Viking TherapeuticsVKTX
VKTX
About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Employees: 34
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
93% more call options, than puts
Call options by funds: $486M | Put options by funds: $252M
72% more repeat investments, than reductions
Existing positions increased: 174 | Existing positions reduced: 101
60% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 58
33% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 8 (+2) [Q3]
20% more capital invested
Capital invested by funds: $4.43B [Q2] → $5.3B (+$866M) [Q3]
8% more funds holding
Funds holding: 385 [Q2] → 416 (+31) [Q3]
0.62% more ownership
Funds ownership: 75.77% [Q2] → 76.39% (+0.62%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$74
125%
upside
Avg. target
$95
189%
upside
High target
$109
232%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 30% 1-year accuracy 118 / 399 met price target | 210%upside $102 | Buy Reiterated | 17 Jan 2025 |
Piper Sandler Biren Amin 15% 1-year accuracy 3 / 20 met price target | 125%upside $74 | Overweight Initiated | 2 Dec 2024 |
B. Riley Securities Mayank Mamtani 26% 1-year accuracy 6 / 23 met price target | 232%upside $109 | Buy Initiated | 22 Nov 2024 |
Financial journalist opinion
Based on 36 articles about VKTX published over the past 30 days
Positive
The Motley Fool
3 hours ago
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?
One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in the real world. You might be familiar with the top sellers, such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy -- they've made headlines as demand for them soared.
Neutral
Zacks Investment Research
13 hours ago
Viking Therapeutics, Inc. (VKTX) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.87, denoting a +0.67% change from the preceding trading day.
Neutral
24/7 Wall Street
16 hours ago
Billionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street Expert
Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence.
Positive
Market Watch
17 hours ago
What's next for Viking Therapeutics? Here's how the company can scale up.
Viking's obesity-drug program is progressing well. Now management is thinking about manufacturing tie-ups.
Neutral
Zacks Investment Research
1 day ago
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Neutral
Accesswire
3 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Negative
The Motley Fool
4 days ago
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of companies selling (or hoping to sell) semaglutide and related drugs for treating diabetes and losing weight. As of 11 a.m.
Neutral
Accesswire
5 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Negative
Zacks Investment Research
6 days ago
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales growth of its tirzepatide products in Q4.
Neutral
PRNewsWire
1 week ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK , Jan. 14, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Charts implemented using Lightweight Charts™